Design Therapeutics Inc (DSGN)

Currency in USD
4.040
-0.020(-0.49%)
Real-time Data·
DSGN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 5 days
DSGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.0404.040
52 wk Range
2.6007.770
Key Statistics
Prev. Close
4.06
Open
4.04
Day's Range
4.04-4.04
52 wk Range
2.6-7.77
Volume
1.02K
Average Volume (3m)
94.34K
1-Year Change
-12.88%
Book Value / Share
4.02
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DSGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.333
Upside
+81.52%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Design Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Design Therapeutics Inc Company Profile

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Design Therapeutics Inc SWOT Analysis


GeneTAC Innovation
Design Therapeutics pioneers geneTAC technology, combining ASO and small molecule approaches to target genetic disorders with high unmet needs
Pipeline Progress
Explore the company's lead assets in Friedreich's ataxia and Fuchs corneal dystrophy, crucial for near-term prospects and platform validation
Market Potential
Analyst targets range from $4 to $12 per share, reflecting diverse views on Design Therapeutics' growth potential in the genetic disorder treatment market
Challenges Ahead
Learn about the early-stage nature of all programs and the potential impact on investor confidence and future funding needs
Read full SWOT analysis

Compare DSGN to Peers and Sector

Metrics to compare
DSGN
Peers
Sector
Relationship
P/E Ratio
−4.1x−3.7x−0.5x
PEG Ratio
−0.800.010.00
Price/Book
1.0x2.9x2.6x
Price / LTM Sales
-161.8x3.3x
Upside (Analyst Target)
23.2%162.0%42.8%
Fair Value Upside
Unlock−2.3%6.5%Unlock

Analyst Ratings

1 Buy
2 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 7.333
(+81.52% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.31 / -0.29
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

DSGN Income Statement

People Also Watch

16.29
SRPT
-2.75%
37.01
EXEL
-1.20%
6.03
REPL
-4.58%
46.039
SMR
+2.02%
10.47
DYN
+2.15%

FAQ

What Stock Exchange Does Design Therapeutics Trade On?

Design Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Design Therapeutics?

The stock symbol for Design Therapeutics is "DSGN."

What Is the Design Therapeutics Market Cap?

As of today, Design Therapeutics market cap is 229.35M.

What Is Design Therapeutics's Earnings Per Share (TTM)?

The Design Therapeutics EPS (TTM) is -0.99.

When Is the Next Design Therapeutics Earnings Date?

Design Therapeutics will release its next earnings report on 10 Aug 2025.

From a Technical Analysis Perspective, Is DSGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Design Therapeutics Stock Split?

Design Therapeutics has split 0 times.

How Many Employees Does Design Therapeutics Have?

Design Therapeutics has 56 employees.

What is the current trading status of Design Therapeutics (DSGN)?

As of 06 Aug 2025, Design Therapeutics (DSGN) is trading at a price of 4.04, with a previous close of 4.06. The stock has fluctuated within a day range of 4.04 to 4.04, while its 52-week range spans from 2.60 to 7.77.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.